October 12, 2012
Dave Hinds is a Principal Scientist in Statistical Genetics. 23andMe is passionate about research on a group of rare blood disorders called myeloproliferative neoplasms, or MPNs. Physicians who study these disorders consider them to be blood cancers, though individual prognoses can vary widely — some [...]
October 9, 2012
Amy Kiefer is a Survey Research Manager at 23andMe. She joined the company in 2008. What do nearsightedness, stretch marks, and motion sickness have to do with each other? They don’t appear to be genetically related — at least not according to our in-house statistical geneticists — but all of them are [...]
October 1, 2012
Ashley Gould, 23andMe's Vice President Corporate Development and Chief Legal Officer We recently topped our goal of enrolling 1,000 people with a group of rare blood disorders known as myeloproliferative neoplasms, or MPNs. As a testament to the passion of the people who’ve enrolled in our MPN Research [...]
September 4, 2012
Dr. Ross Levine Last year 23andMe launched a Myeloproliferative Neoplasms Research Initiative to study this group of rare blood cancers. We are now very close to reaching our goal of enrolling 1,000 patients and are encouraged by what we’ve already learned. We’re also humbled that another star in the [...]
August 2, 2012
Not all cancers are created equal. Ask anyone with metastatic breast cancer. For the 155,000 women in the United States living with this diagnosis, each day represents a constant fight against a cancer that has spread into other parts of their bodies — most often their bones, liver, lungs or brain. With [...]
July 25, 2012
Each person who has joined 23andMe’s Sarcoma research community has their own reasons for participating, but they all share the same hopes that we have — to find the causes for sarcoma and new treatments for this rare cancer. Earlier this month, 23andMe took an important step in that direction when we [...]
July 16, 2012
Janssen Healthcare Innovation, a unit of Janssen Research & Development, LLC, is sponsoring a study in rheumatoid arthritis patients that will be conducted by MediGuard.org (a subsidiary of Quintiles) and 23andMe. The study, called TogetherRA, will enroll approximately 1,000 patients who are currently [...]
July 9, 2012
23andMe is passionate about making discoveries that will benefit you. We give individuals access to their DNA data while in turn translating information they’ve volunteered into meaningful genetic discoveries. Today we’re announcing the acquisition of CureTogether, Inc. a company that we’ve [...]
June 7, 2012
The American Society of Clinical Oncology recently wrapped up its annual meeting, bringing together health care professionals focused on the fight against cancer. The five days were packed with mind-expanding science and encouraging updates on new efforts for research collaboration between doctors, [...]
June 1, 2012
Starting today cancer researchers will be gathering in Chicago at the meeting of the American Society of Clinical Oncology. Researchers and doctors at the annual meeting — the world’s largest oncology conference — will hear about the most promising drugs being developed to fight cancer. They’ll [...]
